Europe - OSL:AZT - NO0010014632 - Common Stock
The current stock price of AZT.OL is 24.2 NOK. In the past month the price decreased by -6.76%. In the past year, price increased by 90.68%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.94 | 45.09B | ||
| 1AE.DE | ARGENX SE | 68.37 | 45.38B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.99B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.83B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.92B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.22 | 1.02B | ||
| NANO.PA | NANOBIOTIX | N/A | 816.27M | ||
| PHIL.MI | PHILOGEN SPA | 20.79 | 692.99M | ||
| IVA.PA | INVENTIVA SA | N/A | 503.48M | ||
| FYB.DE | FORMYCON AG | N/A | 341.03M | ||
| VLA.PA | VALNEVA SE | N/A | 314.10M |
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms and currently employs 55 full-time employees. The company went IPO on 2005-11-04. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Company’s enzymes include cold activeness and salt tolerance. The Company’s divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.
ARCTICZYMES TECHNOLOGIES ASA
Sykehusveien 23
Tromso TROMS NO
Employees: 53
Phone: 4777648900
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms and currently employs 55 full-time employees. The company went IPO on 2005-11-04. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Company’s enzymes include cold activeness and salt tolerance. The Company’s divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.
The current stock price of AZT.OL is 24.2 NOK. The price decreased by -7.63% in the last trading session.
AZT.OL does not pay a dividend.
AZT.OL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AZT.OL.
ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) currently has 53 employees.
ChartMill assigns a technical rating of 8 / 10 to AZT.OL. When comparing the yearly performance of all stocks, AZT.OL is one of the better performing stocks in the market, outperforming 96.5% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to AZT.OL. AZT.OL has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months AZT.OL reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS decreased by -88.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.86% | ||
| ROA | 0.8% | ||
| ROE | 0.86% | ||
| Debt/Equity | 0.01 |
6 analysts have analysed AZT.OL and the average price target is 34.68 NOK. This implies a price increase of 43.31% is expected in the next year compared to the current price of 24.2.
For the next year, analysts expect an EPS growth of 4.61% and a revenue growth 9.85% for AZT.OL